德国那他珠单抗相关进行性多灶性白质脑病
该研究分析德国截至2017年7月上报的292份疑似PML不良反应报告,最终确认142例那他珠单抗治疗多发性硬化患者的PML。7.7%诊断时临床无症状,9.1%死亡,23.8%首次脑脊液JC病毒DNA检测阴性,提示现有诊断标准需修订并应密切监测。
要点
- 那他珠单抗相关PML可在临床无症状时被诊断,占7.7%。
- 首次脑脊液JC病毒DNA检测阴性不能排除早期PML。
- 血清抗JC病毒抗体阴性不排除日后发生PML,需定期监测。
核心结论
- 确诊PML患者中7.7%诊断时临床无症状,9.1%死亡。
- 首次脑脊液JC病毒DNA检测在23.8%患者中不可测,早期PML敏感性有限。
- 3例PML诊断前6至18个月抗JC病毒抗体阴性,抗体阴性不排除日后发生PML。
研究设计与样本
- 分析德国国家主管机构截至2017年7月收到的292份疑似PML不良反应报告。
- 排除不符合PML诊断标准或信息不足者,最终确认142例PML患者。
主要发现
- 142例确诊PML患者中72.3%为女性,中位年龄43岁(范围19-69)。
- 7.7%诊断时临床无症状,9.1%死亡,40%影像学报告幕下病灶。
- 23.8%患者首次脑脊液JC病毒DNA检测不可测。
临床怎么用
- 对那他珠单抗治疗患者应密切定期进行血清学、影像学和临床监测。
- 早期PML脑脊液JC病毒DNA可阴性,临床和影像表现可不典型,需警惕。
- 抗JC病毒抗体阴性不能排除日后PML,不应据此放松监测。
局限性
- 基于不良反应报告,可能存在报告偏倚和信息不完整。
- 仅纳入德国上报病例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate characteristics relevant to diagnosis of JC polyomavirus-associated progressive multifocal leukoencephalopathy (PML), and PML risk stratification in a large national cohort of patients with multiple sclerosis during therapy with natalizumab. METHODS: Analysis of 292 adverse drug reaction forms on suspected cases of PML reported to the German national competent authority until July 2017. Patients not fulfilling PML diagnostic criteria or with insufficient information available were excluded. RESULTS: Of the 142 confirmed patients with PML, 72.3% (95% confidence interval [CI] 64.4%-79.1%) were women, and the median age was 43 years (range 19-69). Of these patients, 7.7% (95% CI 4.3%-13.5%) were clinically asymptomatic at time of PML diagnosis. PML was fatal in 9.1% (95% CI 5.3%-15.1%) of the patients. Infratentorial lesions on imaging were reported in 40% (95% CI 32.0%-48.6%) of the patients. JC polyomavirus DNA in CSF was undetectable at time of first analysis in 23.8% (95% CI 17.3%-31.9%) of the patients. Three patients tested negative for anti-JC polyomavirus antibodies within 6 to 18 months before PML diagnosis, with seroconversion confirmed 5.5 months, 7 months (in a post hoc analysis only), or at time of PML diagnosis. CONCLUSIONS: JC polyomavirus DNA detection in CSF has limited sensitivity in early PML, and clinical and imaging presentation may be atypical. Thus, critical revision of current PML diagnostic criteria is warranted. Negative anti-JC polyomavirus antibodies in sera do not preclude the later development of PML. This emphasizes the need for close and regular serologic, imaging, and clinical monitoring in patients treated with natalizumab.
引用
- Blankenbach K, Schwab N, Hofner B, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology. 2019. PMID: 30952796. doi:10.1212/WNL.0000000000007451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。